An anti‐factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A

Emicizumab in the Treatment of Acquired Haemophilia: A Case Report

(2019) Patrick Möhnle et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

(2019) Koji Yada et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

(2019) Steven W Pipe et al.   Lancet Haematology

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

(2018) Yesim Dargaud et al.   HAEMATOLOGICA

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

(2018) K. Nogami et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

(2018) Yesim Dargaud et al.   HAEMATOLOGICA

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

(2018) Johnny Mahlangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan

(2017) Yoshiyuki Ogawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

(2016) Midori Shima et al.   NEW ENGLAND JOURNAL OF MEDICINE

A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects

(2015) N. Uchida et al.   BLOOD

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

(2014) A. Muto et al.   BLOOD

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

(2013) A. Muto et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

(2012) F. Baudo et al.   BLOOD

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

(2012) P. KNOEBL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

(2012) Takehisa Kitazawa et al.   NATURE MEDICINE

A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies

(2012) Tomoko Matsumoto et al.   THROMBOSIS AND HAEMOSTASIS

Management of acquired haemophilia A

(2011) P. W. COLLINS   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A

(2009) Tomoko Matsumoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

(2008) E. BERNTORP   HAEMOPHILIA